Cargando…

In vivo Pharmacokinetic/Pharmacodynamic (PK/PD) Target Characterization of the Novel, Long Acting Echinocandin CD101 against C. albicans and C. glabrata in the Neutropenic Murine Disseminated Candidiasis Model

BACKGROUND: CD101 is a novel, long acting echinocandin. The purpose of the study was to evaluate the PK/PD activity of CD101 against C. albicans (CA) and C. glabrata (CG) using the murine neutropenic disseminated candidiasis model. METHODS: 4 CA and 3 CG strains were used. MICs were determined by CL...

Descripción completa

Detalles Bibliográficos
Autores principales: Lepak, Alexander J, Zhao, Miao, Vanscoy, Brian, Ambrose, Paul G, Andes, David R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631110/
http://dx.doi.org/10.1093/ofid/ofx163.1224
Descripción
Sumario:BACKGROUND: CD101 is a novel, long acting echinocandin. The purpose of the study was to evaluate the PK/PD activity of CD101 against C. albicans (CA) and C. glabrata (CG) using the murine neutropenic disseminated candidiasis model. METHODS: 4 CA and 3 CG strains were used. MICs were determined by CLSI standards. Single dose plasma PK was determined in groups of three mice after IP doses of 1, 4, 16, and 64 mg/kg. For treatment studies, mice were rendered neutropenic via administration of cyclophosphamide at days -4, -1, +2 and +4. Mice were infected with 6.3 ± 0.1 CFU/mL (CA) or 6.2 ± 0.2 CFU/mL (CG) injected into the lateral tail vein. Treatment dose range was 0.016 – 64 mg/kg, given once by IP injection 2 hours after infection. Experiment duration was 7 days at which point kidneys were aseptically harvested for CFU counts. The Emax Hill equation was used to model the dose–response data to PK/PD index AUC/MIC. The static and 1-log kill doses, as well as associated total and free AUC/MIC values were determined for each isolate. RESULTS: CD101 MICs were 0.008–0.06 mg/L for CA and 0.06 – 0.5 mg/L for CG. Single dose plasma PK parameter ranges include: Cmax 2.6–77 mg/L, AUC(0-∞) 93–4046 mg*hours/L, T(1/2) 28–41 hours. Dose-dependent cidal activity was observed with a maximal kill of over 2 log(10) CFU/kidney. Average 24 hours AUC over 7 days was used to model AUC/MIC data and fit the treatment response data well (CA R(2) 0.70, CG R(2) 0.86). The static dose (SD) and 1-log kill dose and associated total and free AUC/MIC values are shown (Table). CONCLUSION: CD101 demonstrated in vivo potency in the neutropenic murine disseminated candidiasis model against select CA and CG strains. Similar to studies with other echinocandins, AUC/MIC fit the exposure-response data well and CG targets were numerically lower than CA. However, while CA target range was similar, CG target range was almost 10-fold lower compared with other echinocandins. DISCLOSURES: B. Vanscoy, Cidara: Research Contractor, Research support; P. G. Ambrose, Cidara: Research Contractor, Research support; D. R. Andes, Cidara: Grant Investigator, Research support